{
    "2019-02-18": [
        [
            {
                "time": "2019-02-18",
                "original_text": "沪港通十大成交活跃股排名（2月18日）",
                "features": {
                    "keywords": [
                        "沪港通",
                        "成交活跃",
                        "恒瑞医药"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-02-18",
                "original_text": "今日资金抢入六只强势股一览（2019年2月18日）",
                "features": {
                    "keywords": [
                        "资金抢入",
                        "强势股",
                        "恒瑞医药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-02-16",
                "original_text": "【医药-恒瑞医药(600276)】江琦、王超（研究助理）：业绩靓丽，2019仍将是创新药丰收年-20190216",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "创新药",
                        "业绩靓丽"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-02-18",
                "original_text": "券商评级:三大指数全线大涨 九股迎掘金良机",
                "features": {
                    "keywords": [
                        "券商评级",
                        "指数大涨",
                        "掘金良机"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "消费"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-02-18",
                "original_text": "医疗保健：国内肿瘤临床试验行业数据分析 荐3股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "肿瘤临床试验",
                        "数据分析"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-02-18",
                "original_text": "拟10送2派2.2元，恒瑞医药高开逾3%",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "分红预案",
                        "高开"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-02-18",
                "original_text": "国金证券：恒瑞医药买入评级",
                "features": {
                    "keywords": [
                        "国金证券",
                        "买入评级",
                        "恒瑞医药"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-02-18",
                "original_text": "恒瑞医药2018年报点评：收入逐季加速，创新药开花结果",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "年报",
                        "创新药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-02-18",
                "original_text": "北上资金流入贯穿本轮反弹 百亿元资金扫货贵州茅台",
                "features": {
                    "keywords": [
                        "北上资金",
                        "贵州茅台",
                        "反弹"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "消费"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}